ABSTRACT
nterleukin-2 (IL-2) is a multifunctional cytokine active on T, B, and natural killer (NK) cells and monocytes (1) By interacting with its receptors (IL-2R), IL-2 directs cytotoxic differentiation, proliferation, and cytokine secretion in lymphoid cells. The IL-2/IL-2R system is one of the best characterized in terms of signal transduction (2) that follows receptor triggering, at least in T cells (for reviews, see references 3 and 4) The high-affinity IL-2R is composed of three chains (α, β, and γ), whereas the IL-2Rβγ represents the intermediate affinity receptor, which is necessary and sufficient for IL-2 signaling. The main intracellular signaling pathways that have been implicated up to now in IL-2R triggering originate from the cytoplasmic portion of the IL-2R β chain, which associates to JAK1 (3-5) Both JAK1 and JAK3, which associates to the common γ chain of the IL-2R (6) , are rapidly phosphorylated after cytokine receptor stimulation (7, 8) The activation of JAK1 and JAK3 induces homodimerization of STAT3/STAT5, their migration to the nucleus, and activation of gene transcription in T cells (9, 10) Moreover, the cytoplasmic region of the IL-2Rβ chain can activate p21 ras via Shc/Grb2/Sos (3, 4) , with consequent activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) signaling cascade (3, 4, 10) The ERK/MAPK pathway can also be induced by IL-2 through the activation of phosphatidylinositol (PI)-3 kinase via IL-2Rβ chain (11, 12) , which, however, can independently activate other downstream signals, such as Akt/PKB and specific protein kinase C (PKC) isoforms. Of note, the pleiotropic effects of IL-2 in NK cells--consisting of the induction of cell proliferation, lymphokine activated killer cell generation, and cytokine secretion--have been at least partially dissected at the level of the IL-2R. In particular, although the β chain appears as mostly responsible for the lymphokine activated killer cell generation and proliferative effects of IL-2, the α chain of the receptor is apparently involved in the signaling that leads to cytokine secretion (13) During the past decade, several lines of evidence hinted at the key role of nuclear phospholipase C (PLC) activity in cell proliferation and differentiation of cells of mesenchymal origin (14) (15) (16) (17) However, the signal transduction machinery at the nuclear level is still not well understood. Because the β 1 isoform of PLC has been specifically localized in the nucleus of several cell types (16, (18) (19) (20) (21) (22) , we were interested in analyzing a possible nuclear signaling pathway involving the inositol lipid cycle upon IL-2 stimulation in NK cells.
Here we show that nuclear PLC activity in primary human NK cells is positively regulated by IL-2 within 1 h of stimulation. This activity is due to the β family of PLC. We also show that the IL-2-dependent activation of nuclear PLCβ in NK cells is under the control of MAPK/ERK, whose activation, in turn, is at least partially responsible for the proliferation of NK cells under the effect of IL-2.
MATERIALS AND METHODS

Cytokines, antibodies, and reagents
Human recombinant IL-2 was purchased from Sigma (St. Louis, MO) Phycoerythrin conjugated anti-CD16 (CD16-PE) monoclonal antibody (mAb) was purchased from Becton Dickinson (San Jose, CA) Antibodies against PLCs were generously given by Dr. S. G. Rhee (Lab. Cell Signal., NHBL, NIH, Bethesda, MD) and have been previously characterized (reference 23 and I references therein) Anti-β-tubulin (mAb) was purchased from Sigma. The antibody against ERK protein, reacting with both ERK-1 and ERK-2, was obtained from Santa Cruz Biotechnology (Santa Cruz, CA) Polyclonal antibody against phospho-p44/42 MAPK was obtained from New England Biolabs (Beverly, MA) Monoclonal antibody to phosphoserine (clone 16B4, an IgM) was purchased from Alexis Biochemicals (Laufelfingen, Switzerland) The selective PI-specific PLC inhibitor 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (ET-18-OCH 3 ) (24) was purchased from Calbiochem (La Jolla, CA) and dissolved in ethanol at the stock concentration of 10 mM. PD 98059 (MEK-1 inhibitor) (25) was purchased from New England Biolabs and dissolved in DMSO at the stock concentration of 100 mM. The DNA polymerase α inhibitor aphidicolin was purchased from Sigma and dissolved in phosphate-buffered saline at the stock concentration of 50 µM.
NK cell purification and cytokine treatment
NK cells were isolated from peripheral blood lymphocytes (PBLs) of normal voluntary donors by immunomagnetic negative selection using the Vario-MACS and the NK cell isolation kit (Milteny Biotech, Gladbach, Germany), according to the manufacturer's protocol. In brief, PBLs were separated from buffy coats by Ficoll-Hypaque gradient centrifugation. After plastic adherence, PBLs were magnetically labeled with a cocktail of hapten-conjugated mAbs to CD3, CD4, CD19, and CD33 of mouse IgG 1 isotype, followed by anti-hapten antibody-coupled MACS microbeads. The magnetically labeled cells were then depleted on a depletion column in the magnetic field of a Vario-MACS. Purity of NK cells was immediately checked by anti-CD16-PE labeling and FACS analysis of a small aliquot of the obtained sample. Only samples with a purity exceeding 95% were used.
Purified NK cells (1×10 6 cells/ml) were stimulated with 100 U/ml of IL-2 for periods ranging from 30 min to 48 h, as indicated. Control samples were incubated for the same time periods in the absence of the cytokine.
In some experiments, 100 µM ET-18-OCH 3 , 10 µM PD 98059, or 5 µg/ml aphidicolin were administered to NK cells 30 min before the addition of IL-2. Control samples received an equal amount of the respective solvent. As a control, we have also used 2 µM U-73122 (BIOMOL Research Laboratories, Plymouth Meeting, PA) instead of ET-18-OCH 3 as a PLC inhibitor, which gave the same inhibitory effect (data available on request)
Isolation of nuclei
A hypotonic shock combined with non-ionic detergent, essentially described by Manzoli et al. (17) , has been used. In addition to 0.5 mM phenylmethylsulfonyl fluoride, 10 mM β-mercaptoethanol, 1 mM ethylene glycol-bis(aminoethyl ether) tetraacetic acid, 10 µg/ml leupeptin, 0.3 µM aprotinin, 15 µg/ml calpain I inhibitor, and 7.5 µg/ml calpain II inhibitor were also added to the buffers. Nuclear purity was assessed by detection of β-tubulin as previously described (26) Only nuclei showing a complete absence of β-tubulin in Western blot were used in the reported experiments.
Preparation of cytoplasmic fraction
The cytoplasmic fraction, which is constituted by cytoplasm plus non-nuclear membranes, was obtained by homogenizing cells with 20 strokes in a Dounce homogenizer (in 10 mM Tris-Cl, pH 7.8; 2 mM MgCl 2; and protease inhibitors) and then pelleting the nuclei at 400 × g. Throughout the manuscript, cytoplasm and cytoplasmatic fraction refer to this postnuclear fraction. This procedure allows the recovery of pure cytoplasmic fraction and avoids the risk of contamination by nuclear debris that is present in the crude supernatant from nuclear purification.
PLC and ERK/MAPK assays
PLC assay was carried out exactly as described previously using [
3 H] phosphatidylinositol 4,5-bisphosphate (PIP 2 ) as substrate (27) . For inhibition of PLC activity by anti-PLCβ 1 mAb, which recognizes both PLCβ 1 a and b (21), nuclei were lysed by hypotonic shock and lysate nuclear protein was incubated with the neutralizing antibody exactly as previously described (15) . ERK/MAPK activity was analyzed by using the Biotrak MAPK assay from Amersham (Arlington, IL), according to the manufacturer's instructions.
Immunochemical analysis
Proteins from purified nuclei and cytoplasmatic fractions (60 µg) were separated on 8% polyacrylamide/0.1% SDS gels and transferred to nitrocellulose paper. PLC isoforms, MAPK, and phospho-MAPK were detected with an electrochemiluminescence method.
Immunoprecipitation of activated nuclear MAPK and in vitro phosphorylation of recombinant PLCβ 1
Phosphorylated MAPK was immunoprecipitated from nuclear lysates as previously described (19) . Five hundred nanograms of recombinant wild-type PLCβ 1 or PLCβ 1 95 , in which the putative MAPK phosphorylation site PSSP (amino acids 980-983) was mutated to PSGP (27a), were incubated with the immunoprecipitated MAPK from unstimulated human NK cells and IL-20-treated cells (60 min) in a reaction containing 10 mM HEPES, pH 8.0; 100 µM ATP; 1 µCi [γ-32 P]ATP; 10 mM MgCl 2 ; 0.5 mM benzamidine; and 1 mM DTT for 30 min. Proteins were separated on 8% polyacrylamide/0.1% SDS gels and visualized by autoradiography. Samples incubated in the absence of [γ-
32 P]ATP were used for PLC activity as described previously.
Measurement of diacylglycerol (DAG) mass in the living cells
The assay was performed according to Divecha et al. (28) by using DAG kinase enzyme purified from rat brain. DAG was extracted from nuclei, dissolved in 20 µl of 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfonate (9.2 mg/ml), and sonicated at room temperature for 15 s. After the addition of 80 µl of reaction buffer (50 mM Tris acetate, pH 7.4; 80 mM KCl; 10 mM magnesium acetate; and 2 mM EGTA), the assay was started by the addition of 20 µl of DAG kinase enzyme followed by 80 µl of reaction buffer containing 5 mM ATP and 1 µCi of [γ-32 P]ATP. Incubation was for 1 h at room temperature. Then, phosphatidic acid was extracted, chromatographed, and autoradiographed, and its standard curves were obtained as reported by Divecha et al. (28) by using 1,2-dioleyl-3-palmitoyl-glycerol as substrate.
H-Thymidine uptake assay
Purified NK cells stimulated for 6 or 48 h with IL-2 in the presence or absence of the inhibitors listed previoulsy were assayed for proliferation by 3 H-thymidine uptake. In brief, NK cells were cultured in duplicate wells in a 96-well flat-bottom plate (5×10 4 cells, 100 µl/well) for the established time in the presence of IL-2, and pulsed for the last 6 h of incubation with 3 Hthymidine (1 µCi/well, Amersham) The incorporated radioactivity was measured using an automated liquid scintillation counter.
RESULTS
Nuclear PLC activity in NK cells is up-regulated by IL-2
Nuclear purity was assessed by the detection of β-tubulin, which is reported in Figure 1 . The immunochemical analysis indicates that the β-tubulin, which is a reliable marker for cytoplasmic contamination (29) , was completely absent from the nuclear preparations we have dealt with but was highly represented in the cytoplasmic fractions.
Administration of 100 U/ml of IL-2 to freshly purified NK cells induced a specific activation of nuclear PLC, as detected by the PLC assay on isolated nuclei. The kinetic of IL-2-induced PLC activation showed a peak after 60 min of stimulation and showed a decrease to the basal level of activity after 120 min. However, no changes in PLC activity were detected in the cytoplasmic fraction ( Fig. 2A ) This in vitro PLC assay has been paralleled by the measurement of the actual mass of nuclear DAG after IL-2 treatment of living NK cells. Figure 2B shows that IL-2 treatment induced an increase of this pool of DAG in the same time frame (60 min) of PLC activation and with a similar magnitude of increase, clearly indicating that IL-2 specifically stimulated a nuclear PLC activity. This is consistent with only nuclear PLC being activated, because the increase in nuclear DAG mass reflects the total increase in whole cells (Fig. 2B) . Time courses of PLC activation and DAG production differ from those observed in quiescent, synchronized 3T3 fibroblast, possibly because of differences between established cell lines and primary human cells.
Members of the PLCβ family are the only isoforms expressed in the nucleus of human NK cells
To directly investigate which PLC family was involved in the nuclear PLC response of fresh NK cells to IL-2 stimulation, we next examined the expression of the various PLC isoforms and their subcellular localization in NK cells by Western blot analysis of both cytoplasmic and nuclear fractions from purified NK cells. As shown in Figure 2C , three members of the β family are expressed in the nucleus of NK cells: PLCβ 1 b, which is the splice variant almost entirely nuclear (19, 21) ; PLCβ 2 ; and PLCβ 3 . PLCβ 4 is not expressed in these cells. Both PLCγ (namely γ1 and γ2) and PLCδ are found only in the cytoplasmic fraction of these cells. The previous data demonstrate an activation of nuclear PLC signaling upon IL-2 stimulation of primary human NK cells and assign to the PLCβ family the role of a target for the signal originated from the plasma membrane. In this respect, it has been previously shown that the nuclear localization of PLCβ 1 isozymes depends on the peculiar cluster organization of the lysine residues in the COOH terminal domain (30) IL-2 induces translocation to the nucleus of MAPK and serine phosphorylation of nuclear PLCβ 1 It has been previously demonstrated that nuclear PLCβ 1 is not activated by the canonical Gqα/11 system but undergoes phosphorylation after both IGF-I and insulin stimulation of quiescent murine fibroblasts (19, 31) . Furthermore, this enzyme of the β family (either a or b splice variants) is the only one possessing a putative ERK/MAPK consensus sequence Pro-Ser-Ser-Pro (residues 980-983) in the COOH terminus (23) . The existence of this consensus sequence was a possible clue to check the presence and the activity of MAPK/ERK in nuclei from IL-2-stimulated NK cells as well as to analyze the effect of the MEK-1-specific inhibitor PD 98059 on nuclear PLC activity.
The kinetics of both MAPK enzyme activity (Fig. 3A) and the immunochemical analysis by anti-ERK-1 and ERK-2 antibody (Fig. 3B, left) showed that IL-2 was capable of inducing a marked nuclear translocation of ERK-2 (p42) and ERK-1 (p44), albeit to a lesser extent within 30 min of stimulation. The same nitrocellulose stripped and reprobed with antiphosphorylated MAPK antibody showed that activated ERK-2 and ERK-1 translocated to the nucleus (Fig. 3B, right) . The amount of intranuclear MAPK further increased at 60 min from the beginning of stimulation with the cytokine (Fig. 3B, left and right) . This was accompanied by an increase of nuclear kinase activity as well as by a decrease of the cytoplasmic kinase activity (Fig. 3A) . Therefore, NK cells were pretreated with the selective MEK-1 inhibitor PD 98059.
We analyzed the effect of PD98059 vs. the PLC inhibitor ET-18-OCH 3 on nuclear PLC activity in vitro and on the actual mass of nuclear DAG. We found that ET-18-OCH 3 induced inhibition of nuclear PLC activity both in control and IL-2-treated NK cells, whereas PD 98059 induced inhibition of nuclear PLC only in NK cells stimulated with IL-2 (Fig. 4A) . Figure 4B shows that the same effects produced by ET-18-OCH 3 and PD098059 on PLC activity are detectable when measuring DAG mass in living cells. These findings hinted at a regulatory role of ERKs on nuclear PLC activity upon IL-2 stimulation. Moreover, we have established that the stimulation of nuclear activity is due only to the activation of nuclear PLCβ 1 , because, in the presence of neutralizing anti-PLCβ 1 mAb, the activation induced by IL-2 treatment is completely abolished (Fig. 4C ).
We therefore immunoprecipitated nuclear PLCβ 1 , and, after checking the blot for the presence of this isoform, we reprobed it with an antibody against phosphoserine (Fig. 3C) . The amount of immunoprecipitated PLCβ 1 correlates with the level of expression of this PLC, shown in Figure  2C , and the immunoprecipitated isoform corresponds to the β 1 b splice variant detected in isolated nuclei. The anti-phosphoserine antibody did not stain the nuclear PLCβ 1 b from control cells, whereas in response to a 60-min stimulation with IL-2, we detected a high level of immunoreactivity. The phosphorylation of nuclear PLCβ 1 b is abolished if the cells are incubated for 1 h with PD 98059 before IL-2 stimulation (Fig. 3C ).
To further this issue, we immunoprecipitated phospho-ERK1/2 from nuclei of both unstimulated and IL-2-stimulated (60 min) NK cells and combined with recombinant PLCβ 1 either wild-type or mutated for serine 982, substituted with glycine (S982G), with surrounding motif PSSP, that is, the MAPK consensus sequence. The in vitro phosphorylation assay in the presence of [γ-32 P]ATP (Fig. 3D) showed that wild-type PLCβ 1 was phosphorylated only by phospho-ERK1/2 immunoprecipitated from IL-2-stimulated cells, whereas S982G mutant was not phosphorylated at all. Moreover, the increase of PLC activity was observed only in phosphorylated PLCβ 1 (Fig.  3D) .
Inhibition of the ERK2/nuclear PLCβ pathway inhibits the IL-2-dependent proliferation of NK cells
Because 60 min of stimulation of NK cells with IL-2 was too short to produce a clearly visible cell proliferation (data not shown), we checked thymidine uptake as the index of cell proliferation at later time points. To directly prove whether the IL-2-driven NK cell proliferation was dependent on the ERK2/nuclear PLCβ 1 pathway or not, NK cells were treated with ET-18-OCH 3 , PD 98059, and with the DNA polymerase α inhibitor aphidicolin as independent positive control. The proliferation of IL-2-stimulated purified NK cells was significantly (P<0.01) inhibited by both ET-18-OCH 3 and PD 98059 (Fig. 5 ) in the absence of cytopathic effects. In this context, it should be emphasized again that the nuclear, but not the cytoplasmic PLC, activity in NK cells is affected by IL-2.
DISCUSSION
We and other investigators have established that most mammalian cells utilize an autonomous nuclear signaling to mediate their response to critical survival, proliferation, and differentiation factors (23, 28, 32) . To date, the PI turnover is the nuclear signaling pathway that has been more extensively characterized and associated to specific events of cell proliferation and differentiation in various cell lines under the effect of growth factors (18, 33) . The IL-2/IL-2R system is well characterized in terms of signal transduction. Binding of IL-2 to its receptor can, in fact, activate a variety of intracellular pathways, including the JAK/STAT and ERK/MAPK pathways. Of note, in T cells, both the JAK/STAT and ERK/MAPK pathways have been implicated in the induction of cell proliferation by IL-2 (34, 35) . ERK/MAPK, as well as PI3K, has been reported to also be involved in cytotoxic granule secretion in NK cells (36) (37) (38) . Our data demonstrate the involvement of nuclear PLC, a key enzyme in the turnover of nuclear phosphoinositides, in the response of primary human NK cells to IL-2. NK cells have a prominent cytoplasmic expression of PLCγ 1 and γ 2 (39) (40) (41) (42) (43) . The PLCβ family, however, is predominantly localized in the nucleus of NK cells, although it is also at the plasma membrane. IL-2 up-regulates the nuclear PLC activity in primary NK cells.
Inhibition of PLC activity by ET-18-OCH 3 in IL-2 stimulated NK cells blocks their IL-2-driven proliferation, suggesting that PLC is involved in the onset of NK cell proliferation, similarly to what has been observed in 3T3 mouse fibroblasts stimulated either by IGF-I and insulin (18, 19) . In 3T3 cells, PD 98059, a specific MEK-1 inhibitor, inhibits the nuclear PLC activity induced by insulin as well as the mitogenic effect of this growth factor (19) . On this basis, we treated IL-2-stimulated NK cells with PD 98059, which inhibited the nuclear PLC activity and cell proliferation. In this respect, primary NK cells stimulated with IL-2 apparently respond to PD 98059 differently from the NK cell line YT, whose proliferative activity was reported not to be inhibited by PD 98059 (36) . It is worth mentioning that our results on the antiproliferative effect of PD 98059 have been obtained using a 10-fold lower concentration of the inhibitor, which is not toxic, than that capable of blocking NK cell cytotoxicity (36, 37) . This could account for the high degree of specificity of the inhibitor in the cell cycle progression of NK cells after IL-2 stimulation.
Upon treatment of NK cells with IL-2, MAPK translocated to the nucleus, and PLC-β 1 was phosphorylated on serine residues. In this context, it should be recalled that at amino acids 980-983, PLCβ 1 (both 1a and 1b) displays a typical MAPK consensus sequence, that is Pro-Ser-SerPro (23) , and that in mouse fibroblasts, this PLC when located in the nucleus is phosphorylated by MAPK upon mitogenic stimulation (19) . It is of great interest that such a sequence does not exist in other isoforms of the β family of PLC (i.e., β 2 , β 3 , and β 4 ), and this is in agreement with the fact that IL-2 activates only nuclear PLCβ 1 . A direct confirmation comes from the in vitro phosphorylation experiment, which shows that serine 982, with surrounding PSSP motif, is the phosphorylation site of activated MAPK and that the phosphorylation is responsible for the increase of PLCβ 1 activity.
Taken together, these findings demonstrate that nuclear PLC activity in NK cells is downstream of the IL-2R and that that nuclear PLCβ1 is activated upon its phosphorylation by MAPK. The proposed mechanism of regulation of nuclear PLC by ERK-2 constitutes a link between the previously reported evidence of the role of MAPK in several NK functions and the downstream target in the nucleus. In addition, the stimulation of PLC activity upon treatment of primary human NK cells takes place only in the nucleus, whereas cytoplasmic PLC is unaffected, in agreement with all the previous reports showing that when nuclear inositol lipid cycle is activated, no variation occurs at the cytoplasmic level (44) (45) (46) (47) . This strengthens the evidence that PLCγ, which is a typically cytosolic enzyme (30) , is not involved in the IL-2-mediated activation of human NK cells, because we did not find any activation of cytoplasmic PLC activity after IL-2 treatment.
The finding that a specific PLC (PLCβ 1 b) is localized to the human NK cell nucleus and is linked to the IL-2 response paves the way to the further understanding of what signaling mechanism takes place. It is possible that nuclear PLCβ 1 b is responsible for the maintenance of the optimum amount of PIP 2 inside the nucleus itself, because a PIP 2 -dependent mechanism has been shown to exist in chromatin remodeling after T lymphocyte receptor stimulation (48) . Given the data reported by Sun et al. (24) showing a role for DAG-mediated PKC stimulation in nuclei during the G 2 /M phase transition as well as our data showing selective nuclear translocation of PKC α following nuclear PLC activation (26), we cannot exclude that PLCβ 1 b could control IL-2-driven NK cell proliferation by DAG-mediated PKC activation. This is supported by the fact that nuclear DAG generation, elicited by IL-2, is inhibited by PD 98059 at the same time this compound inhibits nuclear PLC activity and that thereafter, NK cells cease to proliferate. We have also used ET-18-OCH3, as PLC inhibitor, which mimics in our conditions the effect of PD 98059. ET-18-OCH3 is known to inhibit phosphocholine cytidiltransferase (49) , but in our study, it did not lead to an elevation of DAG mass (Fig. 4) , suggesting that the effect was specifically targeted to the nuclear PLC activity. A specific role for nuclear PLCβ 1 in cell cycle control has been assigned in that its overexpression resulted in increased expression of cyclin D3 and its related cyclin-dependent kinase 4, promoted phosphorylation of retinoblastoma protein and increased the binding activity of E2F transcription factor (50) , and accelerated the progression through the G1 phase and entering the S phase of Friend erythroleukemia cells. A similar mechanism could also take place in human NK cells.
On the whole, our data demonstrate that nuclear PLCβ 1 and, in general, the autonomous nuclear signaling in terms of phosphoinositides turnover, are downstream targets of the MAPK pathway stimulated by IL-2 in NK cells and are key steps in the proliferative response of the human NK cell to IL-2. 
